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Epithelial to Mesenchymal Transition as a Predictor of Response to Polo-Like Kinase 1 
Inhibition-Induced Apoptosis in Non-Small Cell Lung Carcinoma  
Pavitra Viswanath, B.E 
Faye M. Johnson, MD, PhD 
 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death 
worldwide. Outcomes are poor for patients with recurrent, advanced or metastatic NSCLC. Polo-
like kinase 1 (PLK1), involved in the regulation of mitotic processes and the response to DNA 
damage, is overexpressed in NSCLC. Inhibiting PLK1 may be an effective treatment for NSCLC 
patients as it is involved in the mechanisms of resistance to several chemotherapy drugs. PLK1 
inhibition or knock-down has various effects in cancer cells, including mitotic arrest, apoptosis, 
and senescence. Predictive biomarkers have not been identified to select those patients who are 
likely to respond to PLK1 inhibitors although a small subset of NSCLC patients respond well to 
single agent therapy. 
Our lab found that mesenchymal NSCLC cell lines were more sensitive to PLK1 inhibitors 
than the epithelial cell lines in vitro. The induction of an epithelial phenotype using miR-200 
expression increased resistance to PLK1 inhibition, whereas the induction of a mesenchymal 
phenotype using ZEB1 expression or TGF-β increased PLK1 inhibition–induced apoptosis. To 
elucidate the mechanisms of resistance to PLK1 inhibition, our lab compared gene and protein 
expression in sensitive and resistant NSCLC cell lines and we identified β-Catenin, SMAD4 and 
PDK1 to be differentially regulated between epithelial and mesenchymal NSCLC cell lines after 
PLK1 inhibition. We tested the role of β-Catenin, SMAD4 and PDK1 in PLK1 inhibition induced 
apoptosis in NSCLC. 
Here, we demonstrate that mesenchymal NSCLC tumors are more sensitive to PLK1 
inhibition compared to epithelial NSCLC in vivo in patient derived-xenograft (PDX) models as 
well as orthotopic mouse models in which the EMT properties are manipulable by modulating the 
miR200/ZEB1 axis. To facilitate analysis of these in vivo studies, we developed a novel semi-
automated method of metastatic lung tumor burden calculation from computed tomography 
images by the calculation of the mass of the thoracic cavity. This method takes into account the 
aggregate tumor metastases in the thoracic cavity which significantly accounts for tumor burden 
in lung adenocarcinoma and provides details about the dynamic processes that occur in vivo over 
time.  
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Chapter 1: Introduction 
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1. Non-Small Cell Lung Cancer 
Lung cancer is one of the deadliest cancers in the world. It is estimated that there 
will be 154,050 deaths and 234,030 new cases of lung cancer in the United States (US) in 
2018 alone (1). The 5-year relative survival rate for lung cancer is 18% (15% for men and 
21% for women) (1). Non-small cell lung cancer (NSCLC) accounts for about 80-85% of 
lung cancers. NSCLCs are classified into three main subtypes by the World Health 
Organization based on histopathology: adenocarcinoma (40% of lung cancers), squamous 
cell carcinoma (25% lung cancers) and large cell carcinoma (10% of lung cancers) (2). 
Some of the rarer types of NSCLC include adenosquamous carcinoma, spindle cell 
carcinoma, giant cell carcinoma, carcinosarcoma, pulmonary blastoma, carcinoid tumors, 
mucoepidermoid carcinoma, adenoid cystic carcinoma and other unclassified carcinoma 
(2). Smoking is the biggest cause and risk factor for lung cancer and is responsible for 
around 80% of lung cancer deaths in the US (1). Some of the other risk factors include 
radon gas exposure, exposure to second-hand smoke, air pollution, asbestos, radiation, 
chromium and cadmium exposure as well as diesel exhaust (1).  
 
2. Known Genetic Alteration in Non-Small Cell Lung Cancer 
In the recent years, genotyping studies in addition to histology have been carried 
out to identify genetic or molecular abnormalities in the various subtypes of NSCLC (3, 
4). Some of the main driver mutations that have been identified include mutations or 
alterations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 
(ALK), KRAS, HER2, BRAF, PIK3CA, and ROS1 (5, 6). These genetic alterations cause 
an increase in tumor cell proliferation, angiogenesis, metastasis as well as decreased 
apoptosis. Many targeted therapies have been developed, targeting these genetic 
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alterations and are outlined in Figure 1.  Many of the kinase inhibitors targeting each of 
these oncogenes are either the standard of care or undergoing active development in the 
clinic, providing a fertile ground for investigations of drug resistance. 
 
 
 
Figure 1: Frequency of molecular aberrations in various driver oncogenes in lung 
adenocarcinomas and current available drugs against these oncogenic proteins. 
Reprinted with permission from Journal of Thoracic Oncology. Tsao AS, Scagliotti GV, 
Bunn PA, Jr., Carbone DP, Warren GW, Bai C, et al. Scientific Advances in Lung Cancer 
2015. J Thorac Oncol. 2016;11(5):613-38. (6) 
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3. Current Systemic Treatments Available to NSCLC Patients 
3.1 Molecularly targeted Therapies 
One of the first driver mutations to be clinically targeted in NSCLC was the 
activating mutations in EGFR. Activating mutations in EGFR most commonly occur as 
either in-frame amino acid deletions in exon 19 or L858R substitutions in exon 21 (7). 
These EGFR mutations tend to make the cancer cells rely on EGFR for survival and this 
is known as oncogene addiction (8). This phenomenon allows the tumors to respond to 
EGFR-specific tyrosine kinase inhibitors (TKIs), such as Erlotinib, Gefitinib, Afatinib and 
Osimertinib. Additionally, the US Food and Drug Administration (FDA) approved kinase 
inhibitors that target ALK-fusion and these include Crizotinib, Ceritinib, and Alectinib. 
Other potential targeted therapies are listed in Figure 1. One of the main barriers that limits 
the effectiveness of kinase inhibitor therapy is the issue of resistance which develops in 
nearly all patients despite robust and durable responses in many (9). Therapy resistance is 
categorized as primary or intrinsic resistance and secondary or acquired resistance. In 
primary resistance, patients lack response to the targeted therapy. In secondary resistance, 
patients initially respond and achieve some benefit after which disease progression is 
observed (9). 
3.2 Cytotoxic Chemotherapy 
Cytotoxic chemotherapy is used as an anticancer treatment for the vast majority of 
NSCLC patients, especially those who do not have any targetable genetic alterations. The 
response to cytotoxic combination chemotherapy is influenced by histology, age, 
comorbidity and performance status (PS) (10). Based on American Society of Clinical 
Oncology (ASCO) standards, the treatment for a patient with PS 0 or 1 is a regimen of a 
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platinum (cisplatin or carboplatin) plus paclitaxel, gemcitabine, docetaxel, vinorelbine, 
irinotecan, or pemetrexed (11). Other chemotherapeutic agents such as paclitaxel, 
docetaxel, vinorelbine, gemcitabine, and irinotecan have shown significant single-agent 
activity in advanced NSCLC(12). As with targeted therapy resistance develops in nearly 
all NSCLC patients. 
3.3 Immunotherapy 
One of the latest breakthroughs in cancer treatment has been immunotherapy, 
which includes targeting the immune-modulating mechanisms that help cancer cells 
defend themselves against the immune system. This approach targets immune checkpoint 
pathways which include the blockade of cytotoxic T-lymphocyte-associated antigen 4 
(CTLA4), programmed cell death-1 (PD-1) and it’s ligand PD-L1, and others (13). 
Ipilimumab is a CTLA4 human IgG1 monoclonal antibody that targets the inhibitory 
interaction between CTLA4 and CD80 or CD86. It is said to deplete tumor-infiltrating 
regulatory T-cells through antibody-dependent cell-mediated cytotoxicity, producing 
elevated levels of cell surface CTLA4 (14). Pembrolizumab and nivolumab are FDA 
approved for the treatment of metastatic NSCLC. Both are humanized monoclonal 
antibodies that inhibit the interaction between the PD-1 coinhibitory immune checkpoint 
expressed on tumor cells and infiltrating immune cells and its ligands, PD-L1 and PD-L2 
(15). 
 
4. Animal Models of NSCLC  
Many genetically engineered mouse models (GEMMS) have been generated that 
encompass a number of mutations found in NSCLC. These include KRAS, BRAF, EGFR, 
LKB1, p53, NFκB (16). Most mouse models for NSCLC are focused on adenocarcinoma 
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where studies have been performed using a Lox-Stop-Lox conditional KRASG12D 
mutation engineered in the endogenous KRAS locus (17, 18). Combining KRASG12D 
activation along with the concomitant inactivation of p53 results in more aggressive 
tumors that also metastasize. The relationship between primary tumor nodules and 
individual metastases could be established in studies in which activation of KRASG12D 
and inactivation of p53 was achieved by infection of mouse lung with lentiviral Cre (19).  
The other type of mouse models that have been used and play a very important 
role in preclinical studies are human xenografts. These include cell line and patient-
derived xenografts (PDXs). In PDX models, direct implantation of small patient tumor 
fragments in immunocompromised mice leads to the development of tumors that may 
accurately represent the heterogeneity of the patient population. These models can be 
serially propagated in mice by subsequent passaging as explants (20). PDX models are 
generated in immunodeficient mice by engrafting patients’ cancerous tissues or cells (21-
26). PDX models are extensively used in preclinical screening and evaluation of drugs for 
various cancers as they accurately depict the patient’s tumors with respect to genetic 
mutations, response to systemic therapy, gene expression and histopathology.   
 
5. PLK Family 
Polo-like kinases (PLKs) are a family of serine-threonine kinases that regulate 
multiple processes such as mitosis, cytokinesis and DNA damage response. PLKs regulate 
the molecular signals that are integrated to initiate and maintain checkpoints that halt the 
progression of cell growth and allow time for DNA repair (27). There are five members 
of the PLK family, named PLK1 to PLK5. The proteins PLK1, PLK2, PLK3 and PLK4 
have similar structures: they have a conserved serine-threonine kinase domain the amino-
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terminal end. PLK1, PLK2 and PLK3 have two regulatory polo-box domains (PBDs) at 
the carboxy-terminal end while PLK4 has one PBD (28). PLK5 is different from the other 
family members as it is a protein that has a PBD but lacks the serine-threonine kinase 
domain (29). The PBD of PLK1 is critical for PLK1 function. Studies have shown that 
that a PBD-dependent protein-protein interaction is critically required for proper M-phase 
progression (30). The PBD functions as a molecular mediator by recognizing a p-Ser/p-
Thr consensus motif (31) and brings the kinase domain of PLK1 in proximity to its 
substrates by interacting with a phosphorylated motif on the substrate itself or its 
associated proteins (32). The PBD-dependent interaction with a phosphorylated target 
occurs by the generation of a phosphorylated binding motif and the binding of PLK1 with 
the resulting target protein (32). This PBD-dependent protein-protein interaction is 
thereby central to various PLK1-mediated biological processes. The structure of PLK 
family proteins is depicted in Figure 2 below. PLK1 is the best characterized of all the 
family members, it is expressed in NSCLC, and it has a well-established role in cancer 
progression. 
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Figure 2: Structure of PLK family proteins 
The open-reading frame amino-acid lengths are shown on the right. The kinase domain is 
depicted in blue while the polo-box domain is depicted in red. The residues that are critical 
for ATP-binding and enzymatic activation (T-loop) within the kinase domains and 
phospho-selectivity within the polo-boxes are indicated.   
9 
 
6. PLK1 Regulation 
Many studies have shown that PLK1 expression as well as activity during the cell 
cycle is regulated at the transcriptional level (33). PLK1 transcription is regulated by 
several transcription factors such as FOXM1, p53 and the E2F family during various 
stages of the cell cycle (34, 35). PLK1 protein activity is regulated by phosphorylation on 
a conserved threonine residue (Thr210) in the kinase domain and this phosphorylation is 
mediated by Bora and Aurora A during normal mitotic entry and after DNA damage 
checkpoint recovery (36). Before entry into mitosis, PLK1 is phosphorylated by Aurora 
A kinase together with Bora, at the Thr210 site, activating it. Bora is able to open up the 
closed formation of PLK1 and Aurora A is able to phosphorylate PLK1 for activation 
during the mitotic entry (37).  Other kinases such as PDK1 and phosphatases have also 
been identified to be involved in the regulation of PLK1 at this residue (34). PLK1 protein 
expression is cell cycle dependent. PLK1 expression is elevated in actively proliferating 
cells and is significantly different among different stages of the cell cycle (38). PLK1 
usually gathers in the centrosome of the spindle poles during the early period of mitosis 
and then migrates gradually from spindle poles to the equatorial plate after entering into 
middle and late period of mitosis. At the end of mitosis, PLK1 gathers in the midbody. 
Therefore, PLK1 expression is barely detectable in G1 and S phase, gradually increases 
in G2 phase, and peaks in M phase (38). PLK1 regulation is also carried out by 
ubiquitination and proteosomal degradation by APC/C which is the ubiquitin ligase for 
PLK1 at mitotic exit (39). 
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7. Role of PLK1 in Cell Cycle Regulation 
The PLK family of serine/threonine kinases are responsible for the control of 
mitotic regulatory networks (34, 38). Some of the cell cycle processes controlled by PLK1 
include mitotic entry (40-42), centrosome maturation (43), chromosome segregation (42, 
44, 45) and cytokinesis (46-48). At the time of cell division, PLK1 localizes to the 
cytoplasm and centrosomes in interphase and concentrates to the kinetochores and 
cytokinetic bridge (49). PLK1 when localized at the centromere contributes to ensure 
accurate chromosome alignment at metaphase and prevents lagging chromosomes at 
anaphase (49). At the time of mitotic entry, PLK1 regulates the activity of CDK1/Cyclin 
B complex and promotes G2/M cell cycle phase transition. The CDK1/Cyclin B complex 
is kept inactive by an inhibitory phosphorylation of CDK1 at Thr 14 and Tyr 15 by WEE1 
and MYT1 kinases respectively, leading to the accumulation of Cyclin B1 during G2 
phase of cell cycle. During the onset of mitosis, PLK1 activates the CDK1/Cyclin B 
complex by two means: by the activating phosphorylation of CDC25 phosphatase (50) 
which is a positive regulator and the inhibitory phosphorylation of MYT1 and WEE1 
kinases which are the negative regulators (51) . In late mitosis, PLK1 regulates the activity 
of APC/C which an E3 ubiquitin ligase responsible for the timely degradation of various 
mitotic regulators. This is also important for the regulation of chromosome segregation, 
mitotic exit and a subsequent stable G1 phase (52).  
 
8. Role of PLK1 in DNA Damage Response 
When DNA damage occurs, cells are unable to proceed into mitosis until the DNA 
is repaired– a process termed the G2 DNA damage checkpoint (53). Inactivation of PLK1 
is a key mediator of this checkpoint.  This checkpoint is particularly pertinent for double 
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stranded breaks as the duplicated DNA can be used as a template for homologous 
recombination; this opportunity is lost after mitosis.  In response to the DNA damage, two 
kinases: ATM (ataxia talangectasia mutated) and ATR (ATM and RAD3-related) are 
activated. ATM and ATR phosphorylate Bora at Thr 501, causing it to be recognized by 
the E3 ubiquitin ligase for degradation (53). Once degraded, however, Bora cannot 
cooperate with Aurora A to facilitate the activation of PLK1 (53).The loss of PLK1 
activity results in CDK1 inactivation, resulting in a G2 arrest. Following DNA repair, Bora 
expression is restored and PLK1 is again activated, allowing for the mitotic entry and 
recovery of cell division.  The DNA damage response is distinct during mitosis.  
Phosphorylation of 53BP1 by CDK1 and PLK1 during mitosis impairs its function by 
inhibiting its ability to bind to ubiqutinated histone H2A (54).  In this way, inhibition of 
PLK1 might enhance DNA repair by non-homologous end joining  during mitosis (55). 
 
9. Effect of PLK1 Inhibition in Cancer 
PLK1 is overexpressed in many cancers such as lung, breast, kidney, head and 
neck carcinoma to name a few (56).  PLK1 is implicated the development of genomic 
instability and aberrant cell proliferation and survival associated with tumorigenesis (57). 
PLK1 is a potential therapeutic target for cancer. PLK1 knockdown decreases cancer cell 
survival, induces apoptosis, and increases sensitivity a number of drugs and has a little 
effect in normal cells (58-60). PLK1 inhibition by RNA interference in cancer cells in 
vitro resulted in mitotic arrest and subsequent apoptosis (61). Some studies have shown 
that tumors with p53 deficiency and/or RAS mutations as well as PLK1 overexpression 
are sensitive to PLK1 inhibitors (62, 63). PLK1 has also been shown to facilitate survival 
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in PTEN depleted prostate cancer cells as PLK1 overexpression is required for PTEN-
depleted cells to adapt to mitotic stress for survival (64).  
 
10. Effect of PLK1 Inhibition in NSCLC 
The 5-year survival rate of the patients with tumors with moderate expression of 
PLK1 was higher (52%) than those with a high level of PLK1 transcript (24%) in the 
tumors (65), thereby making PLK1 a potential target for NSCLC therapy. Also, activating 
mutations in KRAS are common in NSCLC (66) and previous studies have shown that 
RAS mutant cancer cells are sensitive to PLK1 inhibitors (62, 63). Based on a study 
published by our lab, we did not observe a robust, consistent correlation between KRAS 
mutation and PLK1 inhibitor sensitivity in vitro (67).  
A study showed that short hairpin RNAs (shRNAs) against PLK1 reduced the 
growth of A549 NSCLC cells in mouse tumor xenografts and suppressed tumor PLK1 
expression (68). Another study showed that PLK1 inhibition using systemic treatment 
with siRNA inhibited the growth of A549 cells in the mouse liver, thereby showing a role 
for PLK1 in lung cancer liver metastasis (69). Previous studies in our lab showed that 
mesenchymal NSCLC cells were more sensitive to PLK1 inhibition in comparison to 
epithelial NSCLC cells based on differential E-Cadherin mRNA and protein expression 
as well as the 76-gene EMT score developed by the department (67, 70).   
Studies have also shown that PLK1 inhibition is effective in NSCLC with acquired 
EGFR-TKI resistance (71) as well as NSCLC with acquired EGFR-TKI resistance that 
had undergone EMT (72). 
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11. PLK1 Inhibitors in Clinical Development 
Two main types of PLK1 inhibitors have been developed: ATP-competitive kinase 
inhibitors and PBD inhibitors. The ATP-competitive inhibitors target the deep groove in 
the ATP binding serine-threonine kinase domain (73). One of the main drawbacks of the 
ATP-competitive inhibitors is the development of resistance due to high conservation of 
ATP binding domains of different kinases and frequent mutations in the ATP binding sites 
(74). Also, one of the major problems associated with the currently available ATP-
competitive inhibitors is their low degree of selectivity against other kinases, and their 
toxicity could be partly due to their interference with other kinases (75). In order to 
develop more specific inhibitors against PLK1, anti-PLK1 agents that target the PBD 
domain are currently being tested pre-clinically and have demonstrated improved 
specificity towards PLK1 (76). The PBD inhibitors are unique to polo-like kinases and are 
therefore much more specific than inhibitors that target the ATP-binding domain (77).  
The drug used in this study is Volasertib or BI6727, an ATP-competitive PLK1 
inhibitor derived from a dihydropteridinone lead structure (78). Volasertib potently 
inhibits PLK1 and PLK2 with IC50 values of 0.87 and 5 nM, respectively, and shows 
relatively lower potency on PLK3 (56 nM) but does not inhibit PLK4 (>20μM) (78). 
Volasertib inhibits PLK1 which leads to a disruption of the mitotic spindle assembly 
resulting in a distinct mitotic arrest phenotype (known as ‘Polo arrest’) in 
prometaphase, accumulation of phospho-histone H3 and formation of aberrant 
monopolar mitotic spindles followed by apoptosis (78-80). All the PLK1 inhibitors in 
clinical development have been summarized in the table below. 
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Table 1: PLK1 inhibitors in clinical development 
Inhibitor Status Company or Lab Class 
BI2536 Experimental Boehringer Ingelheim 
ATP-
competitive 
GSK461364 Experimental GlaxoSmithKline 
ATP-
competitive 
Volasertib 
(BI6727) 
Experimental Boehringer Ingelheim 
ATP-
competitive 
ZK-
thiazolidinone 
Experimental Bayer Schering Pharmacy 
ATP-
competitive 
Rigosertib 
(ON01910) 
Experimental Onconova Therapeutics Inc. 
ATP-
competitive 
Cyclapolin 9 Experimental Cyclacel 
ATP-
competitive 
GW 843682X Experimental GlaxoSmithKline 
ATP-
competitive 
NMS-937 Experimental Nerviano Medical Sciences 
ATP-
competitive 
SBE 13 
hydrochloride 
Experimental Institute of Organic Chemistry & 
Chemical Biology, Goethe-University 
ATP-
competitive 
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TAK960 
hydrochloride 
Experimental Takeda Pharmaceutical Company 
ATP-
competitive 
Poloxin Experimental Max Planck Institute of Biochemistry 
and Munich Center for Integrated 
Protein Science 
Non-ATP-
competitive 
Poloxin-2 Experimental Institute of Organic Chemistry, 
University of Leipzig 
Non–ATP-
competitive 
RO3280 Experimental Hoffmann-La Roche 
Non–ATP-
competitive 
 
12. Epithelial-to-Mesenchymal Transition (EMT) and Cancer 
Epithelial-to-mesenchymal transition (EMT) is a process that involves the 
transdifferentiation of epithelial cells into motile mesenchymal cells (81). The EMT 
phenomenon plays a very important role in tumor progression and metastasis (82). EMT 
results in the loss of cell–cell contacts and the reorganization of the intracellular 
cytoskeleton thereby leading to increased cell migration and invasion (83). EMT allows 
cancer cells to invade the stroma and vasculature, thereby leading to tumor dissemination 
and metastases (84). More importantly, EMT enables cancer cells to avoid apoptosis, 
anoikis, and oncogene addiction (85). EMT can be easily recognized in the molecular level 
by the reduced expression of epithelial markers such as E-Cadherin and β-Catenin, and 
the elevated expression of mesenchymal markers such as N-Cadherin and vimentin. One 
of the well studied proteins that induce EMT are the two-handed δEF1 family transcription 
factors ZEB1 and ZEB2 (86-88). These transcription factors induce EMT by the 
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suppression of E-Cadherin and other epithelial differentiation genes by binding to the E-
boxes of their promoters (89). MicroRNAs (miRs) are small non-coding RNAs that 
control development and maintenance by pleiotropic regulation of cellular functions 
(90). The microRNA-200 family are expressed in epithelial cells (91). In normal as well 
as cancer epithelial cells, the miR-200 family exists in a double negative feedback loop 
with the ZEB1 and ZEB2 transcriptional repressors (92-95). The ZEB/miR-200 balance 
is regulated by inducers of EMT such as TGFβ, which leads to the loss of miR -200 
expression and a shift to a mesenchymal phenotype (93). 
 A study carried in prostate cancer cells showed that forced overexpression of PLK1 
in prostate epithelial cells led to the downregulation of epithelial markers E-cadherin and 
cytokeratin 19 and upregulation of mesenchymal markers N-cadherin, vimentin, 
fibronectin, and SM22 (96). The studies carried out in our lab showed that mesenchymal 
NSCLC cell lines were sensitive while epithelial NSCLC cell lines were resistant to 
PLK1-inhibition induced apoptosis (67). The cells were defined as epithelial or 
mesenchymal based on a 76-gene EMT score developed by the department (70). 
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13. Hypothesis and Specific Aims 
NSCLC cell lines have diverse sensitivities to PLK1 inhibition, which is consistent 
with the results of clinical trials of PLK1 inhibitors.  However, predictive biomarkers have 
not been used to select patients likely to respond to PLK1 inhibitors, and the mechanisms 
of sensitivity and resistance to PLK1 inhibitors have not been elucidated, making these 
unknowns a major gap in knowledge.  The main goal of the project is to test the hypothesis 
that PLK1 inhibition will cause apoptosis in mesenchymal but not epithelial NSCLC in 
vivo.  Furthermore, to identify the mechanisms of PLK1 inhibitor-induced sensitivity, we 
will test the role of molecules that are differentially expressed or modulated in sensitive 
and resistant NSCLC cell lines. 
Aim 1: To test the hypothesis that PLK1 inhibition will cause apoptosis in 
mesenchymal NSCLC but not epithelial NSCLC in vivo. 
1(a). To test the effects of PLK1 inhibition in epithelial and mesenchymal patient 
derived xenograft (PDX) models. 
A minimum of 14 PDX models is required to have 80% power to detect a spearman 
correlation of 0.7 between the tumor size and E-cadherin score using a 2-sided test at a 
significance level of 0.05. For each model, tumors will be implanted in 25 mice and will 
be monitored daily. Once the tumor reaches a volume of ~150 mm3, the mice will be 
treated with 30 mg/kg of the PLK1 inhibitor Volasertib or vehicle. Tissue for RNA and 
protein analysis will be obtained from the PDX tumors to study gene and protein 
expression. The EMT score, protein and gene expression of E-Cadherin, E-Cadherin 
score, markers of apoptosis, proliferation and target inhibition will be measured. 
1(b). To determine if manipulation of EMT will affect PLK1 inhibition-induced 
apoptosis in an orthotopic, immunocompetent NSCLC mouse model. 
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Cell lines derived from a KrasLA1/+p53R172HΔG/+ (KP) genetically engineered mouse 
model that develop advanced lung adenocarcinomas have EMT properties that are 
manipulable by ectopic expression of ZEB1 or miR-200a/b. The stable 393P cell lines that 
express ZEB1 or the 344SQ cell lines that express miR200 will be injected into syngeneic, 
immunocompetent mice (6-8 week old 129S/V male mice). The induction of miR200 or 
ZEB1 expression will be done through doxycycline dissolved in water. Following 
injection, mice will be randomized into two groups to receive vehicle (control) or 30 
mg/kg Volasertib weekly for 4 weeks. The mice lungs will be imaged by micro-CT once 
a week to measure tumor volume. The lungs of the mice will be collected at the end of the 
experiment for analysis. 
Aim 2: To develop a method for accurate metastatic lung tumor burden calculation 
from CT in an orthotopic mouse model. 
To develop a novel method for accurate lung tumor burden calculation from CT in 
an orthotopic mouse model. The rationale for the development of this method is because 
there is no respiratory gating in the CT, no contrast agents are used to identify tumors thus 
making it difficult to distinguish between tumors and blood vessels and metastatic tumors 
(such as the tumors in the thoracic cavity) are not taken into consideration while 
calculating tumor burden.     
Hypothesis: Mass of Thoracic Cavity does not change over time and observed changes are 
due to tumor burden. 
Aim 3:  To test the hypothesis that molecules that are differentially expressed at 
baseline or differentially modulated following PLK1 inhibition mediate PLK1 
inhibitor-induced apoptosis. 
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Hypothesis: Higher β-Catenin expression in epithelial cells mediates PLK1 inhibition-
induced apoptosis in NSCLC by EMT and interacting with PLK1 in the centrosome. 
SMAD4 mediates sensitivity of mesenchymal NSCLC to PLK1 inhibition-induced 
apoptosis by activation of TGF-β Pathway. Differential modulation of PDK1 following 
PLK1 inhibition mediates PLK1 inhibitor-induced apoptosis by regulating downstream 
survival signaling pathways.  
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Chapter 2: Materials & Methods 
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1. Reagents and Antibodies 
The PLK1 inhibitor Volasertib was purchased from Selleck Chemicals (Houston, 
Texas) and a stock solution of 10mmol/L was prepared in DMSO. The non-targeting 
control, CTNNB1 and SMAD4 SMARTpool siRNAs were purchased from Dharmacon 
(GE Lifesciences) and the sequences are as outlined in Table 1 below: 
 
Table 2: List of siRNA used in the study 
 
GENE TARGET SEQUENCE 
Non-targeting Control 
1. UGGUUUACAUGUCGACUAA 
2. UGGUUUACAUGUUGUGUGA 
3. UGGUUUACAUGUUUUCUGA 
4. UGGUUUACAUGUUUUCCUA 
CTNNB1 
1. GAUCCUAGCUAUCGUUCUU 
2. UAAUGAGGACCUAUACUUA 
3. GCGUUUGGCUGAACCAUCA 
4. GGUACGAGCUGCUAUGUUC 
SMAD4 
1. GUGUGCAGUUGGAAUGUAA 
2. GUACAGAGUUACUACUUAG 
3. GAGUAUUGGUGUUCCAUUG 
4. GUAAUGCUCCAUCAAGUAU  
 
 
PDK1-EGFP overexpression plasmid was kindly provided by Dr. Gordon Mills. The 
antibodies that were used in the study were diluted in 5% BSA in TBST with 0.05% 
NaN3 and are outlined in the table below: 
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Table 3: Description of antibodies used in the study 
 
ANTIBODY COMPANY 
HOST 
SPECIES 
CATALOG NO. DILUTION 
PLK1 
Cell Signaling 
Technologies 
Rabbit 4513 1:1000 
p-PLK1 T210 
Cell Signaling 
Technologies 
Rabbit 9062 1:1000 
PARP 
Cell Signaling 
Technologies 
Rabbit 9532 1:1000 
Cleaved PARP 
Cell Signaling 
Technologies 
Rabbit 5625 1:1000 
Caspase 3 
Cell Signaling 
Technologies 
Rabbit 9665 1:1000 
p-Histone H3 (S10) 
Cell Signaling 
Technologies 
Rabbit 3377 1:1000 
TCTP 
Cell Signaling 
Technologies 
Rabbit 5128 1:1000 
p-TCTP (S46) 
Cell Signaling 
Technologies 
Rabbit 5251 1:1000 
NPM 
Cell Signaling 
Technologies 
Rabbit 3542 1:1000 
p-NPM (S4) 
Cell Signaling 
Technologies 
Rabbit 3520 1:1000 
γ-H2AX (S139) 
Cell Signaling 
Technologies 
Rabbit 9718 1:1000 
E-Cadherin 
Cell Signaling 
Technologies 
Rabbit 3195 1:1000 
Vimentin 
Cell Signaling 
Technologies 
Rabbit 5741 1:1000 
β-Catenin 
Cell Signaling 
Technologies 
Rabbit 8480 1:1000 
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SMAD4 
Cell Signaling 
Technologies 
Rabbit 38454 1:1000 
GAPDH 
Cell Signaling 
Technologies 
Rabbit 5174 1:10000 
Wee1 
Cell Signaling 
Technologies 
Rabbit 13084 1:1000 
p-Wee1 (S642) 
Cell Signaling 
Technologies 
Rabbit 4910 1:1000 
PDK1 
Cell Signaling 
Technologies 
Rabbit 13037 1:1000 
p-PDK1 (S241) 
Cell Signaling 
Technologies 
Rabbit 3438 1:1000 
CMYC 
Cell Signaling 
Technologies 
Rabbit 5605 1:1000 
p-CMYC (S62) 
Cell Signaling 
Technologies 
Rabbit 13748 1:1000 
AKT 
Cell Signaling 
Technologies 
Rabbit 4691 1:1000 
p-AKT (S473) 
Cell Signaling 
Technologies 
Rabbit 4060 1:1000 
4E-BP1 
Cell Signaling 
Technologies 
Rabbit 9452 1:1000 
p-4B-BP1 (S65) 
Cell Signaling 
Technologies 
Rabbit 13443 1:1000 
ZEB1 
Cell Signaling 
Technologies 
Rabbit 3396 1:1000 
PCNA 
Cell Signaling 
Technologies 
Mouse 2586 1:1500 
β-Actin 
Cell Signaling 
Technologies 
Mouse 3700 1:10000 
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2. Cell Culture 
Human NSCLC cell lines were obtained, maintained and genotyped by Short 
Tandem Repeat (STR) profiling as described previously (67). Murine 344SQ cell lines 
with an inducible miR200 expression was kindly provided by Dr. Don Gibbons’ lab. 
Murine 393P cell line with constitutively active ZEB1 was kindly provided by Dr. 
Jonathan Kurie’s lab. The cells were routinely tested for mycoplasma contamination using 
a Mycoplasma detection kit (Lonza). The cell lines were cultured in RPMI-1640 media 
containing 10% Fetal Bovine Serum (FBS) and 2% Penicillin/Streptomycin. The cells 
were maintained in a humidified atmosphere with 5% CO2 at 37°C. 
 
3. Cell Viability Assay 
CellTiter Glo (Promega) luminescent assay was used as per the manufacturer’s 
specifications to determine cell viability based on intracellular ATP levels. In brief, 800 
cells were plated in each well in a 384-well plate. The cells were incubated with 7 different 
concentrations (half-fold serial dilution) of the PLK1 inhibitor Volasertib, the highest 
being 500nM for 72h. The luminescence measured is proportional to the amount of 
intracellular ATP and is an index of cell number. 
 
4. Apoptosis Assay 
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining 
(APO-BrdU kit; BD Biosciences) was used to measure apoptosis. In general, DNA breaks 
and total cellular DNA is labelled to detect apoptotic cells based on the manufacturer’s 
protocol and the data was generated using a flow cytometer (Gallios, Beckman Coulter). 
The data was analyzed using Kaluza (Beckman Coulter).  
 
5. Western Blot 
Sub-confluent NSCLC cell lines were lysed with 1X Cell Lysis Buffer containing 
20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton, 
2.5mM sodium pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4 and 1 μg/ml 
25 
 
leupeptin (Cell Signaling Technology) on ice, The lysed cells were collected and 
centrifuged at 14,000 x g for 15 minutes and the supernatant lysate was collected. The 
protein concentration of the lysates was measured using the Pierce bicinchonic acid (BCA) 
protein assay kit (ThermoFisher Scientific). Lysates of 1μg/μl concentration was prepared 
by mixing with Laemmli Sample Buffer (Bio-Rad Laboratories) and water. Equal amounts 
of proteins from the NSCLC lysates were separated using 4-20% SDS-PAGE gels and 
were immunoblotted with primary antibodies overnight. The proteins were detected with 
horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescent 
substrate (ThermoFisher Scientific). The densitometric quantification of the protein 
normalized to β-Actin was carried out using ImageJ (NIH, Bethesda).  
 
6. Transfection 
For knockdown assays, 1.5 x 106 NSCLC cells were plated in 10cm 24 hours prior 
to transfection. The following day, Lipofectamine RNAiMAX transfection reagent 
(Invitrogen) was mixed in 1X OPTI-MEM Media (Gibco). In a separate tube, the 
SMARTpool siRNA which comprises of a predesigned set of 4 siRNA for the respective 
targets was mixed in 1X OPTI-MEM Media. The siRNA mixture was added to the 
Lipofectamine RNAiMAX mixture and incubated in room temperature for 5 minutes. This 
siRNA-liposomal mixture was then added to the cells and were incubated at 37°C for 72 
hours. Protein lysates were then collected at the aforementioned time point and analyzed 
via western blot. 
For stable transfection of the PDK1-EGFP plasmid, 1.5 x 106 cells were plated 24 
hours prior to transfection. 5μg of plasmid was transfected with the help of Liofectamine 
3000 transfection reagent (Invitrogen) in OPTI-MEM Media (Gibco) and the cells were 
incubated at 37°C for 48 hours. Fresh RPMI1640 medium with 10% FBS was added to 
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the NSCLC cell culture plates, and the NSCLC cells were allowed to recover for 24 hours. 
Transfected NSCLC cells were selected using 700μg/ml Geneticin. 
 
7. Subcutaneous Tumor Implantation for PDX Models 
All animal research was conducted in accordance with The University of Texas 
MD Anderson Cancer Center’s Institutional Animal Care and Use Committee. PDX 
tumors that were growing logarithmically were implanted into the right flank of female 
nude mice (Envigo Harlan Laboratories, Indianapolis). The tumors were measured twice 
a week with the help of Vernier calipers. Tumor volume was calculated by using the 
formula (length x width2)/2. Once the tumor volumes reached ~150mm3, the mice were 
randomized into two groups, control and Volasertib. The mice were treated with 30mg/kg 
of vehicle control or Volasertib intravenously (IV tail vein injection) once a week up to 4 
weeks. The mice were then euthanized and the tumors were excised. Protein was extracted 
from the tumor in order to check for target inhibition, apoptosis and proliferation. Multiple 
row t-tests was used in order to see the differences in tumor volume between the two 
groups over time. 
 
8. Orthotopic Lung Injection in immunocompetent mouse models 
All mice were manipulated and maintained conducted in accordance to UT MD 
Anderson’s Office of Research Administration and IACUC committee guidelines. 129/sv 
male mice at 4-6 weeks of age were purchased from Charles River Laboratory 
(Massachusetts). The mice were of 8 weeks of age and at the start of the experiment.  CT 
imaging of the lungs was carried out to serve as baseline study. The mice were fully 
anesthetized by 2-4% isofluorane inhalation throughout the entire procedure. 
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The mice were placed in a right lateral decubitus position. The lower edge of the 
right rib cage was identified by palpation and the area trimmed with a hair clipper. After 
cleaning with 70% ethanol solution, the area was shaved with a razor blade. Finally, the 
incision site was sterilized with Betadine solution. A 1-cm incision in the skin was be 
made along the lower edge of the rib cage. The cephalic edge of the skin was retracted 
with forceps to reveal the underlying subcutaneous tissue and fat. A second incision was 
made through the fatty tissue to reveal the rib cage and the thoracic cavity. The respiring 
lung was identified as a pale structure under the rib cage, whereas the more caudal spleen 
was identified as a dark read organ. 
Tumor cells (200,000 cells in 50 μl) were injected into the lower third of the left 
lung using an insulin syringe. The left lung was checked for an absence of intra-thoracic 
hemorrhage or collapse prior to closing the incision. Using forceps, the opposing skin was 
held together and stapled with an Auto-clip stapler using two to three 9-mm staples.  
The mice were given 0.05-0.10 mg/kg Buprenorphine analgesic following this 
procedure. The mice were kept warm under a heat lamp and monitored for recovery. The 
cage was returned to the rack when the mice were able to move on all four limbs. 
 
9. Endotracheal Intubation and CT Imaging 
The mice were placed in an inhalation anesthesia induction chamber (Isoflurane 
5% for induction, and 1.5% to 3% for maintenance).  When the mice were fully 
anesthetized, an endotracheal tube (22 gauge x 1 inch length) was placed using a BioLite 
mouse intubation system (Braintree Scientific). The mice were then placed onto a holder 
and moved to the CT system (Precision XRay Incorporated XRAD 225Cx). The CT 
parameters used were 60Kv 4mA and 3RPM.  The mice were mechanically ventilated at 
60BPM throughout the procedure and a 20 second breathe hold was applied during the 
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acquisition at 20cm/H20 (97). The pressure was monitored through an inline manometer. 
After the acquisition was complete, the mice were extubated, and recovered in a clean, 
warm cage until sternal. 
 
10. CT Image Analysis 
Tumor Mass from Mass of Thoracic Cavity  
The CT images were exported in Digital Imaging and Communications in 
Medicine (DICOM) format. The DICOM image sequence was uploaded in Raystation 
5.0.2 Research (Raysearch, Sweden). The lung volume with a constant threshold of -800 
to 0 was determined based on the lung region growing algorithm in order to remove bias. 
A Region of Interest (ROI) was drawn in the chest cavity from the base of the lung to the 
top of the trachea using the smart contour option of Raystation. Mass of the thoracic cavity 
(MTC) was calculated as a function of ROI Volume and CT Intensity. Tumor Mass was 
extrapolated by comparison with the MTC of the mice from the CT images at baseline.   
 
Sum of Cross-Product (SCP) Method 
The quantification of tumor burden by the manual cross-product analysis of micro 
CT images was carried out as previously described (98). The lung micro CT DICOM 
images were viewed in the coronal plane on Fiji (ImageJ) software (http://fiji.sc/Fiji). The 
tumors were visualized in the coronal plane and the largest cross-sectional plane of each 
tumor was identified. From this, the maximal tumor diameter (d1) and the largest 
perpendicular diameter (d2) was determined by placing a ruler on the screen. The total 
tumor burden was then calculated by the sum of cross products (SCP = ∑ (d1* d2)) of all 
tumors per animal. This method has been validated by ex vivo micro CT analysis (98).   
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Tumor & Vessel Volume (T&V) Method 
Tumor and vessel volume was calculated as previously described (99). In brief, the 
functional lung volume was calculated based on a region growing algorithm with a 
threshold value set -800 to 0 voxels chosen empirically based on visual inspection of a 
few mice on Raystation 5.0.2. the total chest space volume excluding the heart was 
calculated using the region growing algorithm and semi-automated contouring. The 
combined tumor and vasculature volume (T&V) was determined by subtracting the 
functional lung volume from total chest space volume (99). 
 
Ellipsoidal Tumor Volume Method 
The images were viewed on MicroView analysis + version 2.2 software (GE 
Healthcare). One to five tumors were identified and selected in each mouse on the axial 
view. The three greatest diameters of each tumor were measured on the axial, coronal and 
sagittal views (referred to as x, y, and z). These values were then used to calculate the 
volume of the tumor using the formula of an ellipsoid ([4/3][x/2][y/2][z/2]) (100, 101). 
 
Aerated Lung Volume Method 
Functional lung volume measurement is a fully automated method that utilized the 
gray-level, morphological and texture features to segment the aerated lung region using a 
region-growing algorithm (102). Measurement of the functional lung volume is an inverse 
surrogate measure of tumor burden (102). The measurement of aerated lung volume was 
done at the last time point of the studies due to lack of respiratory gating facilities.  
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11. Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism 7 software (GraphPad, 
USA). Multiple row t-tests was used to compare changes in tumor volume between control 
and Volasertib treated mice. One-way anova and Tukey’s multiple comparison test was 
used to compare the changes in the mass of thoracic cavity of the disease-free mice. 
Pearson correlation and linear regression was carried out to compute R value for the 
correlation graphs. Unpaired t-tests was used to compare changes in protein expression 
between the NSCLC cell lines. 
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Chapter 3: Results 
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1. EMT markers correlate with PLK1 inhibition in NSCLC cell lines in an independent 
dataset 
In order to identify novel biomarkers of response to PLK1 inhibition, reverse phase 
protein array (RPPA) protein expression data was downloaded from MD Anderson Cell 
Lines Project (MCLP) database (http://tcpaportal.org/mclp/#/) and PLK1 inhibitor 
sensitivity data for BI2536, GSK461364, BRD-K70511574 and GW-843682X were 
downloaded from The Cancer Therapeutics Response Portal V2 (Broad Institute, 
https://portals.broadinstitute.org/ctrp/) for  64-71 NSCLC cell lines (71 for BI2536, 69 for 
GSK461643, 68 for BRD-K70511574 and 64 for GW843682X). Spearman Correlation 
was applied to identify the correlation between drug sensitivity and protein expression 
using R package. Thirty three proteins correlated significantly with sensitivity to two or 
more PLK1 inhibitors (Figure 3). As seen in our previous study, E-cadherin (p<0.001, 
r>0.3), and β-Catenin (p<0.001, r>0.3) protein expression was higher and Snail (p<0.01, 
r>-0.3) and Twist (p>0.05, r<-0.3) protein expression was lower in the NSCLC cell lines 
resistant to the PLK1 inhibitors (103). 
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Figure 3: EMT markers correlate with PLK1 inhibition in a panel of NSCLC cell 
lines in an independent dataset. 
A: Dot plot showing correlation between PLK1 inhibitors (BI2536, GSK461364, BRD-
K70511574 and GW-843682X) sensitivity from CTRPv2 and RPPA data from MCLP 
(104). 
B: Correlations of E-Cadherin, β-Catenin, and Snail with area under the curve (AUC) of 
GSK461364 and BI2536 respectively. 
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2. Mesenchymal NSCLC tumors are more sensitive in comparison to epithelial NSCLC 
tumors to PLK1 inhibition induced apoptosis in patient-derived xenograft (PDX) 
mouse models 
In order to test the hypothesis that mesenchymal NSCLC tumors are more sensitive 
than epithelial NSCLC tumors to PLK1 inhibition induced apoptosis in vivo, 13, 29 or 84 
PDX models are required to have 80% power to detect Spearman correlations of 0.7, 0.5 
or 0.3 between the tumor size ratio and E-Cadherin score using a 2-sided t-test and a null 
hypothesis correlation of 0 at a significance level of 0.5. The PDX tumors were obtained 
from our lab and Dr. Bingliang Fang’s lab (23) and their EMT status was determined by 
E-Cadherin and vimentin protein expression. The tumors with high E-Cadherin protein 
expression were considered epithelial and those with high vimentin expression were 
considered mesenchymal PDX models (Figure 4). We implanted tumors of four different 
PDX models HLC4, TC402, TC424 and TC370 that have diverse EMT status and the mice 
were randomized into two groups, vehicle control and Volasertib. The tumors were 
measured twice a week for 4 weeks after which the tumors were resected.  
In HLC4 PDX model which has an intermediate EMT phenotype based on 
membrane E-Cadherin score which is calculated based on the intensity and completeness 
of membrane E-Cadherin immunostaining (105) (E-Cadherin score 67.4), there was no 
significant change in mean tumor volume at the end of the experiment between the vehicle 
and Volasertib treated mice (p=0.0947) based on Mann-Whitney t-test. Based on multiple 
row t-tests in order to compare tumor volumes between the groups over time, a significant 
decrease in tumor volume was observed from day 6 up to day 24 between vehicle and 
Volasertib treated mice (p<0.05) (Figure 5).  Two out of 10 mice in the Volasertib treated 
group had tumor regression and 8/10 grew on therapy (Figure 5). There was no change in 
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the levels of apoptosis or proliferation based on cleaved PARP and PCNA protein 
expression in the tumor tissues as seen in immunoblotting (Figure 6). PLK1 inhibition was 
demonstrated by the increase in the levels of phosphorylated histone H3 (Ser 10). 
In the epithelial TC402 PDX model, there was a significant decrease in tumor 
volume between the vehicle and Volasertib treated mice (p=0.012) at the end of the 
experiment based on Mann-Whitney t-test. Based on multiple row t-tests to compare 
tumor volumes between the groups over time, a significant difference in tumor volume 
was observed from day 6 until the end of experiment, i.e., day 34 (p<0.05) (Figure 5). Two 
out of 10 mice in the Volasertib treated group had tumor regression and 8/10 tumors grew 
on therapy (Figure 5). There was an increase in the level of phospho histone H3 (S10) in 
the Volasertib treated tumors. There was no significant difference in the levels of cleaved 
PARP or PCNA between the vehicle and Volasertib treated tumors (Figure 6).  
In the mesenchymal TC424 PDX model, there was a significant decrease in tumor 
volume between the vehicle and Volasertib treated mice (p<0.0001) based on Mann-
Whitney t-test. Based on multiple row t-tests to compare tumor volumes between the 
groups over time, a significant difference in tumor volume was observed from day 3 until 
the end of experiment, i.e., day 39 (p<0.05) (Figure 5). Eight out of 10 mice in the 
Volasertib treated group had tumor regression and 2/10 treated tumors grew on therapy 
(Figure 5). There was an increase in the level of phospho histone H3 (S10) in the 
Volasertib treated tumors. There was no significant difference in the levels of cleaved 
PARP or PCNA between the vehicle and Volasertib treated tumors (Figure 6).  
In the mesenchymal TC370 PDX model, there was a significant decrease in tumor 
volume between the control and Volasertib treated mice (p<0.0001) based on Mann-
Whitney t-test. Based on multiple row t-tests to compare tumor volumes between the 
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groups over time, a significant difference in tumor volume was observed from day 3 until 
the end of experiment, i.e. day 34 (p<0.05) (Figure 5). Six out of 10 mice in the Volasertib 
treated group had tumor regression and 4/10 treated tumors grew on therapy (Figure 5). 
There was no change in the level of phospho histone H3 (S10) between the vehicle and 
Volasertib treated tumors. There was no significant difference in the levels of cleaved 
PARP or PCNA between the control and Volasertib treated tumors (Figure 6).  
Together, these data demonstrate that tumor regression is observed in the 
mesenchymal TC424 and TC370 PDX models after PLK1 inhibition while slower tumor 
growth or growth arrest is observed in the intermediate HLC4 and epithelial TC402 PDX 
models (Figure 5). It also suggests that lung tumor heterogeneity might be playing a role 
in mediating response to PLK1 inhibitors.  
38 
 
 
 
Figure 4: PDX tumors have diverse EMT phenotypes 
The epithelial or mesenchymal phenotype of the PDX tumors were determined based on 
E-Cadherin and vimentin protein expression as seen in the immunoblot (lower). The bar 
plot is a quantification of the protein expression (upper). Those tumors with higher E-
Cadherin expression are considered epithelial (as depicted in red text) while those that 
have higher vimentin expression are considered mesenchymal (as depicted in blue text). 
The PDX tumors that express both are considered intermediate (as depicted in black text). 
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Figure 5: Mesenchymal NSCLC PDX tumors are more sensitive to PLK1 inhibition 
induced apoptosis in comparison to epithelial NSCLC PDX tumors 
A: The HLC4 intermediate PDX tumor volumes of control and Volasertib treated mice 
over time are depicted in the left. A significant difference in tumor volume was observed 
from day 6 to day 24. The waterfall plot on the right depict the percentage change in tumor 
burden of each individual mouse at the end point. 
B:  The TC402 epithelial PDX tumor volumes of control and Volasertib treated mice over 
time are depicted in the left. A significant difference in tumor volume was observed from 
day 6 to day 34. The waterfall plot on the right depict the percentage change in tumor 
burden of each individual mouse at the end point. 
C: The TC424 mesenchymal PDX tumor volumes of control and Volasertib treated mice 
over time are depicted in the left. A significant difference in tumor volume was observed 
from day 6 to day 39. The waterfall plot on the right depict the percentage change in tumor 
burden of each individual mouse at the end point. 
D: The TC370 mesenchymal PDX tumor volumes of control and Volasertib treated mice 
over time are depicted in the left. A significant difference in tumor volume was observed 
from day 6 to day 42. The waterfall plot on the right depict the percentage change in tumor 
burden of each individual mouse at the end point. 
E: The overall percent change in tumor volume between the vehicle and Volasertib treated 
mice at the end of the experiment for all the PDX models is depicted. Each data point 
represents one mouse in the respective group. 
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Figure 6: Western blot analysis of PDX tumors for markers of apoptosis, 
proliferation and target inhibition 
Western blot analysis of PDX tumors collected at the end of the experiment was carried 
out to measure protein expression for markers of apoptosis (cleaved PARP), proliferation 
(PCNA) and target inhibition (pHH3 (S10)). The graphs on the right are quantification of 
the markers relative to control.  
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3. Mesenchymal PDX models demonstrate improved survival and sustained tumor 
growth inhibition after cessation of PLK1 inhibition treatment 
In order to assess the potential of PLK1 inhibition to result in sustained tumor 
suppression, 5 mice in both vehicle and Volasertib treated groups of TC424 and TC370 
mesenchymal PDXs were monitored for up to 100 days after the 4-week Volasertib 
treatment ceased. Tumors were measured once a week up to day 100 after which the mice 
were monitored for survival analysis.    
Volasertib treatment was stopped at day 41 after which tumors were measured 
once a week for 100-103 days. Sustained tumor growth inhibition was observed in the 
Volasertib treated mice while the tumors continued to grow in the vehicle-treated mice 
(Figure 7). A significant difference in survival was observed between the two groups in 
both TC424 (p=0.004) and TC370 (p=0.012). The control mice were euthanized within 
108 (TC424) to 140 (TC370) days due to tumor burden while the Volasertib mice were 
alive up to day 150 (TC424) to 140 (TC370) (Figure 7). 
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Figure 7: Sustained tumor growth inhibition is observed in TC424 and TC370 
Mesenchymal PDX models after cessation of Volasertib treatment 
The graphs on the left depict tumor volume over time (up to day 101 or 103) after cessation 
of Volasertib treatment. The mice were then monitored for survival. A significant 
difference in survival between vehicle and Volasertib treated mice was observed.  
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4. Expression of EMT markers are heterogeneous in PDX tumors 
The PDX tumors have diverse EMT expression. The EMT status of the PDX 
tumors were validated at the end of the experiment. Two out of 4 mice in HLC4 PDX 
model have a high expression of E-cadherin in comparison to Vimentin (Figure 6). Based 
on the overall E-Cadherin and Vimentin expression, HLC4 has an intermediate phenotype. 
In TC402 PDX model, the 4 mice have high E-Cadherin expression in comparison to 
vimentin protein expression and thus has an epithelial phenotype. Overall, TC424 and 
TC370 have high vimentin expression in comparison to E-Cadherin and is considered to 
have a mesenchymal phenotype. Interestingly, there are some mice in each PDX model 
that have varying expressions of E-Cadherin and Vimentin (Figure 8). The quantification 
of E-Cadherin and vimentin protein in the different PDX models is depicted in Figure 8 
The H&E stains of the PDX tumors also depicts heterogeneous populations of tumor cells 
(Figure 8).  
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Figure 8: Expression of EMT markers are heterogeneous in PDX tumors 
A: Quantification of E-Cadherin and vimentin expression in the PDX tumors shows that 
HLC4 and TC402 have a more epithelial phenotype with higher E-Cadherin expression in 
comparison to vimentin expression.  
B: The H&E images of the PDX tumors in the vehicle and Volasertib-treated mice depict 
the heterogeneous population of cells present in the lung tumors. 
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5. Epithelial-to-mesenchymal transition by expression of ZEB1 leads to increase in 
sensitivity to PLK1 inhibition induced apoptosis in an orthotopic, syngeneic NSCLC 
mouse model 
To test the hypothesis that PLK1 inhibition will cause apoptosis in mesenchymal 
NSCLC but not epithelial NSCLC in vivo, we used syngeneic murine cell lines derived 
from a KP GEMM in which EMT properties are manipulable by the ectopic expression of 
miR200 a/b and ZEB1 (106).  
393P cells transfected with vector alone (epithelial) or ZEB1 (mesenchymal) were 
injected into 55 mice with 5 mice serving as negative control, i.e., mice with no cancer 
cells injected. CT imaging was carried out at baseline and once a week for 4 weeks. Pilot 
experiments demonstrated that mice developed tumors by day 10.  The two groups of mice 
(vector, ZEB1) were each randomized into 2 groups at day 10 (Volasertib, vehicle).  This 
design resulted in 4 groups: 393P vector + vehicle, 393P vector + Volasertib, 393P ZEB1 
+ vehicle and 393P ZEB1 + Volasertib. Each group consisted of 9-10 mice. The mice were 
treated with vehicle or 30mg/kg of Volasertib by IP injections once a week for 4 weeks. 
The mice were euthanized at the end of the experiment and the lungs were collected. 
In the epithelial 393P vector model, Volasertib led to a decrease in tumor mass 
(method described in detail below) on day 31 but the change was not statistically 
significant (p=0.08) using Mann-Whitney t-test statistical method. The 393P cells with 
ZEB1 overexpression were slower growing in vivo in comparison to the 393P Vector cells. 
We observed a significant decrease in tumor mass in the 393P ZEB1 mice treated with 
Volasertib in comparison to the 393P ZEB1 vehicle control mice (p=0.011) as determined 
by one way anova (Figure 9A, C). In the 393P vector mice treated with Volasertib, 3/10 
tumors regressed while 7/10 tumors grew on therapy. In the 393P ZEB1 mice treated with 
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Volasertib, 7/10 tumors regressed and 3/10 tumors grew on therapy. The overall percent 
change in tumor mass at day 31 in the four groups is depicted in Figure 9B which 
demonstrates that tumor regression was observed in the mesenchymal 393P ZEB1 mice 
treated with Volasertib in comparison to the 393P Vector group where growth arrest of 
tumors was observed. Representative CT images as well as 3D representation of changes 
in tumor mass in all the four groups is also depicted (Figure 9E). The results are 
recapitulated in the H&E staining. It can be seen that the 393P vector mice treated with 
Volasertib still have tumor cells present in the lung while the 393P ZEB1 mice treated 
with Volasertib has very few or no cancer cells present (Figure 9F). 
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Figure 9: Disease progression in 393P Vector and 393P ZEB1 orthotopic mouse 
model treated with vehicle control or Volasertib 
A: The figure represents the tumor mass of mice in the 4 over groups over time. The dotted 
line represents the start of Volasertib or vehicle control treatment, i.e. day 10. 
B: The bar graph represents the percent change in tumor mass in the 4 groups at day 31. 
Tumor regression was observed in the 393P ZEB1 mice treated with Volasertib. 
C: The graph depicts the percent change in tumor mass in the 393P vector group treated 
with vehicle control or Volasertib and the 393P ZEB1 group treated with vehicle control 
or Volasertib.  
D: The waterfall plot depicts the percent change in tumor mass at day 31. 
E: The figures on the left depict the CT images of the lung tumors in the four groups 393P 
Vector control, 393P Vector treated with Volasertib, 393P ZEB1 control and 393P ZEB1 
treated with Volasertib. Also shown is the 3D representation of the MTC calculated to 
measure tumor mass.  
F: The figure represents the H&E staining of lungs from negative control, 393P vector and 
393P ZEB1 mice treated with either vehicle or Volasertib. 
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6. Tumor mass calculated from the Mass of Thoracic Cavity (MTC) of mice with 
metastatic lung adenocarcinoma gives an accurate quantification of metastatic 
tumor burden. 
To address the need for a semi-automated, unbiased method for the in vivo 
quantitative assessment of lung tumor mass in mice, we used micro CT without respiratory 
gating to estimate the tumor mass. With a basic assumption that aerated MTC of the adult 
mice does not change over time unless due to disease progression, our imaging and 
analysis protocol permits comparison between different groups, enables evaluation over 
time in individual animals and provides specific information on the progress of metastases. 
Moreover, we confirm the validity and thereby extend the applicability of our lung tumor 
mass analysis in an orthotopic lung xenograft mouse model. 
In order to test the assumption that the MTC does not change over time unless 
there is change in tumor burden, five healthy mice with no tumors were imaged 
periodically at the same time as the mice with the metastatic lung adenocarcinoma (details 
below) and the MTC was calculated over time by drawing the region of interest (ROI) 
from the base of the lungs to the top of the trachea. There was no change in the MTC over 
time, and the percent change in the mass of thoracic cavity was ±0.2, p>0.9999 based on 
one-way anova and Tukey’s multiple comparison analysis (Figure 10). No changes in 
MTC were observed despite breath hold stage of the mice.  The summary of the anova 
results is outlined in Table 4.  
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Table 4: Tukey’s multiple comparison results for changes in MTC 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI of 
diff. 
Significant? Adjusted P 
Value 
0 vs. 12 -0.5499 -763.4 to 762.3 No >0.9999 
0 vs. 19 -3.183 -766 to 759.6 No >0.9999 
0 vs. 26 -1.919 -764.7 to 760.9 No >0.9999 
0 vs. 33 -2.15 -765 to 760.7 No >0.9999 
12 vs. 19 -2.633 -765.4 to 760.2 No >0.9999 
12 vs. 26 -1.369 -764.2 to 761.4 No >0.9999 
12 vs. 33 -1.6 -764.4 to 761.2 No >0.9999 
19 vs. 26 1.264 -761.5 to 764.1 No >0.9999 
19 vs. 33 1.033 -761.8 to 763.8 No >0.9999 
26 vs. 33 -0.2314 -763 to 762.6 No >0.9999 
 
To test the proposed method we used the orthotopic KP GEMM model in which 
the mice were imaged at baseline and the MTC was calculated. The 344SQ mouse lung 
adenocarcinoma cells were then injected into the left lung of the mice via orthotopic 
injection. The mice were then serially imaged and the MTC was calculated on days 12, 
19, 26 and 33 to study the course of tumor development.  The tumor mass was then 
calculated by subtracting the MTC on the specific day from the MTC at baseline. The 
workflow is as depicted (Figure 11). The mice survived for an average of 3 weeks after 
the orthotopic injection of the metastatic mouse lung adenocarcinoma cells. The mice were 
euthanized when they were moribund or at the end of 4 weeks on day 33 immediately after 
the last micro-CT imaging session. The mice were necropsied, the number of primary and 
metastatic tumors were counted and the lungs were collected and weighed.  
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Figure 10: The Mas of Thoracic Cavity does not change over time 
The graph on the left depicts that the MTC of adult mice does not change over time. The 
graph on the right depicts the percent change in the MTC of mice. No changes in MTC 
were observed irrespective of breath hold stage of mice.  
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Figure 11: Tumor mass calculated from the Mass of Thoracic Cavity of mice with 
metastatic lung adenocarcinoma gives an accurate quantification of metastatic 
tumor burden 
The flowchart depicts the workflow used to calculate MTC from CT Images and tumor 
mass calculation. 
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7. Lung tumor burden quantification of MTC method as well as existing methods 
significantly correlated with lung weight 
We compared multiple methods of lung tumor burden measurement: MTC 
method, the RECIST-like Sum of Cross-Products (SCP) method (98), segmentation of 
aerated lung volume (102) without respiratory gating, volumetric measurement of 
combined tumor and vasculature from a threshold-based region growing algorithm with 
manual and semi-automated segmentation (99)  as well as ellipsoid tumor burden 
measurement (107). In order to determine the intrinsic accuracy of each method to 
measure tumor burden, the tumor burden of 10 mice with lung adenocarcinoma was 
calculated from each method was correlated with the gold standard, i.e., lung weight. The 
correlation values of lung weight with MTC (r=0.78, p=0.005), tumor burden from SCP 
(r=0.63, p=0.03), ellipsoid tumor volume (r=0.78, p=0.004), tumor and vessel volume 
(r=0.65, p=0.02) as well as aerated lung volume (r=-0.69, p=0.01) validated the ability of 
these methods to accurately determine tumor burden in mice with lung adenocarcinoma 
(Figure 12). 
The tumor burden values from all these methods was plotted against tumor mass 
calculated by the proposed MTC method.  Tumor burden calculation from the SCP method 
significantly correlated with tumor mass calculated from MTC method (p=0.0085, r=0.74) 
(Figure 13). The SCP method is very similar to the RECIST guideline which is a 
standardize measure of tumor response, especially in clinical trials (108). There was no 
significant correlation between ellipsoid tumor volume and tumor mass (p=0.13, r=0.48), 
tumor & vessel volume and tumor mass (p=0.12, r=0.49) and end point lung volume and 
tumor mass (p=0.12, r=-0.48). This may be due to the small sample size (n=10) (Figure 
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13). Table 5 outlines the various features of the MTC method as well as the other CT 
analysis methods that have been used for tumor burden measurement.  
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Figure 12: Lung tumor burden quantification of existing methods besides the MTC 
method significantly correlated with lung weight 
A: Tumor mass calculated from MTC significantly correlated with lung weight. 
B: Tumor burden calculated by SCP Method significantly correlated with lung weight. 
C: Ellipsoid tumor volume significantly correlated with lung weight. 
D: Tumor & Vessel volume significantly correlated with lung weight. 
E: End point lung volume significantly correlated with lung weight. 
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Figure 13: Correlation of tumor mass with tumor burden from SCP method, 
ellipsoid tumor volume, tumor + vessel volume and end point lung volume 
A: Tumor burden calculated from the RECIST-like MCP method significantly correlated 
with tumor mass calculated from MTC 
B: Ellipsoid tumor burden correlated with tumor mass calculated from MTC 
C: Tumor + Vessel volume correlated with tumor mass calculated from MTC 
D: End point lung volume correlated with tumor mass calculated from MTC 
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Table 5: Summary of MTC and other CT analysis methods 
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8. Validation study for MTC method shows that Volasertib treatment reduced tumor 
mass in a mesenchymal metastatic, orthotopic mouse model 
In order to test the MTC method in an independent dataset, we tested the effect of 
the PLK1 inhibitor Volasertib in an orthotopic mouse model. 25 mice were imaged at 
baseline. We injected 344SQ cells which were derived from a KP mouse model into the 
left lung of 20 mice. 5 mice served as negative control, i.e., mice in which cancer cells 
were not injected. The mice were then serially imaged at days 12, 19, 26 and 33. At day 
12, the mice had tumors of treatable size and were randomized into two groups, and treated 
with vehicle control or 30mg/kg of Volasertib intravenously for 4 weeks. The percent 
tumor mass increased more than 10 fold in the vehicle treated mice while the percent 
change in tumor mass increased approximately 2.4 fold in the Volasertib treated mice over 
the 4 week period. There was significant difference in percent change in tumor mass 
between the control and Volasertib treated mice on days 19 (p=0.035), 26 (p= 0.008) and 
33 (p=0.004) based on multiple t-test analysis (Figure 14). The percent change in tumor 
mass at day 33 was significantly different between the control and Volasertib treated mice 
(p=0.03) based on non-parametric Mann-Whitney t-test analysis (Figure 14). The H&E 
images show that the lungs of the vehicle treated mice have many tumor cells present 
while the lungs of the Volasertib treated mice have very few tumor cells remaining. This 
data also supports the hypothesis that mesenchymal NSCLC tumors are sensitive to PLK1 
inhibition in vivo in an orthotopic, immunocompetent mouse model. 
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Figure 14: Validation study for MTC method shows that Volasertib treatment 
reduced tumor mass in a mesenchymal metastatic, orthotopic mouse model 
A: The graphs depict the percent change in tumor mass over time from day 12 to day 33. 
Volasertib treatment significantly reduced tumor mass in the 344SQ mouse model 
B: The waterfall depicts the percent change in tumor mass between the vehicle and 
Volasertib treated mice at the end of the experiment. Each bar represents mouse. 
C: The graph depicts a significant difference in percent change in tumor mass between the 
control and Volasertib treated mice on day 33.  
D: The figure depicts tumor progression in the Control and Volasertib treated mice at 
baseline and days 12, 19, 26 and 33. The CT images and the 3D representation of MTC is 
depicted.  
E: The figure represents the H&E staining of lungs from negative control, 344SQ mice 
treated with either vehicle or Volasertib. 
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9. β-Catenin knock-down (KD) did not reverse resistance to PLK1 inhibition induced 
apoptosis in epithelial NSCLC cell lines that express high levels of β-Catenin  
Because of the striking differential expression of β-Catenin between sensitive and 
resistant NSCLC cell lines, we hypothesized that β-Catenin might mediate resistance to 
PLK1 inhibitors (67).  In order to elucidate the mechanism for EMT-induced sensitivity 
to PLK1 inhibition, Dr. Ratnakar Singh compared changes in 303 protein/phosphoprotein 
expression after PLK1 inhibition using RPPA in 3 epithelial and 3 isogenic pairs (treated 
with TGFβ) and two additional mesenchymal sensitive cell lines (Calu-6 and H1792). In 
order to identify the molecule or signaling pathway responsible for driving resistance to 
PLK1 inhibition, we looked for common proteins that were differentially expressed in 
epithelial and mesenchymal NSCLC cell lines after Volasertib treatment.  A decrease in 
β-Catenin protein expression was observed in mesenchymal but not epithelial NSCLC cell 
lines after PLK1 inhibition (Figure 15A). β-Catenin mRNA expression was higher in a 
panel of epithelial NSCLC cell lines in comparison to mesenchymal NSCLC cell lines 
(p=0.0106).  (Figure 15B). 
We hypothesized that knockdown of β-Catenin in the epithelial NSCLC cell lines 
would make them more sensitive to PLK1 inhibition induced apoptosis.  siRNA was used 
to silence β-Catenin. 2 mesenchymal (Calu6 and H1792) NSCLC cell lines was treated 
with 10nM of siRNA targeting β-Catenin (CTNNB1) for 72h. Two epithelial (H1975 and 
HCC366) NSCLC cell lines were treated with 20nM of siRNA targeting β-Catenin 
(CTNNB1) for 72h. The control groups of the cell lines were treated with 10nM of non-
targeting siRNA. The cells were also treated with 50nM of the PLK1 inhibitor Volasertib 
or vehicle for 48h. The drug was added 24 hours after the siRNA transfection. Protein 
lysate was collected from the cells and β-Catenin, PARP, Caspase 3, and phospho-
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nucleophosmin (Ser 4), which is a downstream target of PLK1, were measured by western 
blot analysis (Figure 15C). There was no significant difference in the levels of cleaved 
PARP or cleaved Caspase 3 after β-Catenin KD and PLK1 inhibition despite achieving 
good knockdown of the protein (Figure 15C).  Likewise, there was no significant 
difference in the percentage of apoptotic cells measured by Apo BrdU TUNEL assay 
between the control and β-Catenin KD cells after PLK1 inhibition (Figure 15 D).  
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Figure 15: β-Catenin knock-down (KD) did not reverse resistance to PLK1 inhibition 
induced apoptosis in epithelial NSCLC cell lines that express high levels of β-Catenin  
A: RPPA data depicting the changes in β-Catenin protein expression after PLK1 inhibition 
in epithelial and mesenchymal (as well as isogenic mesenchymal, i.e., epithelial cells 
treated with TGFβ) NSCLC cell lines 
B: Differential β-Catenin mRNA expression between epithelial and mesenchymal NSCLC 
cell lines 
C: Western blot showing that there is no significant difference in the levels of cleaved 
PARP or cleaved Caspase 3 after β-Catenin KD and PLK1 inhibition 
D: Apo BrdU TUNEL assay measuring PLK1 inhibition induced apoptosis after β-Catenin 
KD in NSCLC cell lines. No difference in BrdU positive cells is observed after β-Catenin 
KD and Volasertib treatment. 
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10. SMAD4 knock-down (KD) did not change sensitivity to PLK1 inhibition induced 
apoptosis in NSCLC cell lines 
SMAD4 mutant head and neck squamous cell carcinoma (HNSCC) cell lines were 
more sensitive to Volasertib than SMAD4 wt HNSCC cell lines (109). The same 
correlation could not be carried out in NSCLC cell lines due to the small number of 
SMAD4 mutant cell lines (n=4) but there was  a negative correlation between SMAD4 
mRNA expression and the AUCs of 3 different PLK1 inhibitors Volasertib (p<0.0001, r 
= -0.8841), GSK461362 (p<0.0001, r = -0.5556) and NMS-937 (p<0.0001, r = -0.6595) , 
the AUC calculated from an in house drug study in 70 NSCLC cell lines (67) (Figure 
16A). There was no difference in SMAD4 mRNA expression in a panel of epithelial and 
mesenchymal NSCLC cell lines (p=0.4827).  (Figure 16B). We treated three pairs of 
epithelial NSCLC cell lines that had been treated with TGF and two additional 
mesenchymal NSCLC cell lines with 50nM Volaserib for 24 hours and then subjected the 
cells to RPPA.  No change in SMAD4 protein expression was observed in NSCLC cell 
lines after PLK1 inhibition (Figure 16C).  
We hypothesized that knockdown of SMAD4 in the mesenchymal NSCLC cell 
lines would make them more sensitive to PLK1 inhibition induced apoptosis.  siRNA was 
used to silence SMAD4. 2 mesenchymal (Calu6 and H1792) and 2 epithelial (H1975 and 
HCC366) NSCLC cell lines was treated with 10nM of siRNA targeting SMAD4 for 72h. 
The control groups of the cell lines were treated with 10nM of non-targeting siRNA. The 
cells were also treated with 50nM of the PLK1 inhibitor Volasertib or vehicle for 48h. The 
drug was added 24 hours after the siRNA transfection. Protein lysate was collected from 
the cells and SMAD4, PARP, Caspase 3, and phospho-nucleophosmin (Ser 4), which is a 
downstream target of PLK1, were measured by western blot analysis (Figure 16D). There 
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was no significant difference in the levels of cleaved PARP or cleaved Caspase 3 after 
SMAD4 KD and PLK1 inhibition despite achieving good knockdown of the protein.  
(Figure 15D).  Likewise, there was no significant difference in the percentage of apoptotic 
cells measured by Apo BrdU TUNEL assay between the control and SMAD4 KD cells 
after PLK1 inhibition (Figure 16 E).  
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Figure 16: SMAD4 knock-down (KD) did not change sensitivity to PLK1 inhibition 
induced apoptosis in NSCLC cell lines 
A: Correlation of SMAD4 mRNA Expression with AUCs of Volasertib, GSK461364 and 
NMS-937 
B: There is no differential SMAD4 mRNA expression between epithelial and 
mesenchymal NSCLC cell lines 
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C: RPPA data depicting the changes in SMAD4 protein expression after PLK1 inhibition 
in epithelial and mesenchymal (as well as isogenic mesenchymal, i.e., epithelial cells 
treated with TGFβ) NSCLC cell lines 
D: Western blot showing that there is no significant difference in the levels of cleaved 
PARP or cleaved Caspase 3 after β-Catenin KD and PLK1 inhibition 
E: Apo BrdU TUNEL assay measuring PLK1 inhibition induced apoptosis after SMAD4 
KD in NSCLC cell lines. No difference in BrdU positive cells is observed after SMAD4 
KD and Volasertib treatment 
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11. PDK1 overexpression in a sensitive mesenchymal NSCLC cell line leads to resistance 
to PLK1 inhibition induced apoptosis 
In order to elucidate the mechanism for EMT-induced sensitivity to PLK1 
inhibition, we compared changes in 303 protein/phosphoprotein expression after PLK1 
inhibition using RPPA using the same set up as mentioned previously. Thirty three 
proteins/phosphoproteins were differentially regulated at cutoff p<0.05. These data 
revealed differential effects on both the cMET/FAK/SRC signaling axis (103) (and the 
PI3K/AKT pathway. Western blot analysis of the members of the PI3K/AKT pathway 
confirmed a significant decrease in PDK1 and 4E-BP1 phosphorylation and total protein 
levels in mesenchymal cell lines but not in epithelial cell lines after Volasertib treatment 
(Figure 17).  
In order to test the hypothesis that PDK1 is a driver of resistance to PLK1 
inhibition induced apoptosis, we created a stable PDK1 overexpressing mesenchymal 
NSCLC cell line. The PDK1-EGFP plasmid was kindly provided by Dr. Gordon Mills and 
was stably transfected into the H1792 mesenchymal NSCLC cell line. Overexpression of 
PDK1 protein was biologically active in H1792 cell line as evinced by increased 
downstream S6 (S235/236) phosphorylation (Figure 18A). Overexpression of PDK1 in 
H1792 cell line increased resistance to PLK1 inhibition compared to parental cell lines as 
seen by decrease in cleaved PARP (p=0.007) and γH2AX levels (p=0.003) (Figure 18A-
B). We also observed an increase in percent cell viability in the PDK1 overexpressing 
cells in comparison to the parental cells as tested by CellTitre Glo assay but it was not 
statistically significant (p=0.31). This result was recapitulated using APO BrdU TUNEL 
assay where H1792 PDK1 overexpression cells showed less apoptosis in comparison to 
parental cells after treatment with Volasertib (p=0.003) (Figure 18D). 
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Figure 17: PDK1 protein expression is altered after PLK1 inhibition in mesenchymal 
but not epithelial NSCLC cell lines 
A: 33 proteins are differentially regulated between epithelial and mesenchymal (including 
isogenic) NSCLC cell lines after Volasertib treatment, one of them being PDK1. 
B: 70 proteins are differentially expressed between parental epithelial and mesenchymal 
NSCLC cell lines after Volasertib treatment, including PDK1.  
C: RPPA data shows the changes in pPDK1 (S241) and total PDK1 after Volasertib 
treatment in epithelial and mesenchymal NSCLC cell lines 
D: Western blot shows differential protein expression in certain PI3K proteins such as 
PDK1 and 4E-BP1 between epithelial (cell lines depicted in red) and mesenchymal (cell 
lines depicted in blue) NSCLC cell lines after Volasertib treatment.  
 
NOTE: 17 A-C printed with permission from R.Singh 
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Figure 18: PDK1 overexpression in a sensitive mesenchymal NSCLC cell line leads 
to resistance to PLK1 inhibition induced apoptosis 
A: Western blot of H1792 parental and PDK1 overexpression cell lines treated with 50nM 
Volasertib for 48h. A decrease in cleaved PARP and γH2AX levels are observed in H1792 
PDK1 cell line compared to parental cell line after Volasertib treatment. The PDK1 is 
functional as seen by increase in pS6 (S235/236) and PLK1. 
B: Quantification of cleaved PARP and γH2AX protein levels in H1792 PDK1 and 
parental cell lines after Volasertib treatment. The H1792 PDK1 cells seem to be more 
resistant to Volasertib treatment in comparison to the parental cells. 
C: CellTitre Glo data shows that H1792 PDK1 cells are more resistant to Volasertib in 
comparison to parental cells. 
D: APC BrdU TUNEL assay shows that the H1792 PDK1 cells are resistant to Volasertib 
in compared to parental cells by around 10%.  
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Chapter 4: Discussion  
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Discussion 
Accurate preclinical models are an essential component to performing translational 
cancer research, including discerning molecular pathways of oncogenesis and evaluating 
therapeutics. One of the main rationales for developing PDX models is based on the 
expectation that these models will be more predictive of human cancer biology and patient 
response to treatments. These models are useful for the study of cancer biology, biomarker 
development, drug screening, and the preclinical evaluation of personalized medicine 
strategies. PDX models tend to retain the histological characteristics of donor tumors such 
as tissue structure and gland architecture, mucin production or cyst development. PDX 
models of NSCLC have similar gene copy number (110), mRNA (22) and protein (111) 
and retain specific ‘driver’ mutations of the matching primary tumor (26, 112).  
Our studies demonstrated surprising heterogeneity in PDX tumors derived from 
the same, established models. It is now well established that cancer is genetically 
heterogeneous in an inter- and intra-individual manner and that there is a genetic evolution 
in cancer as the tumor progresses (113). Thus, a PDX model generated from one individual 
lesion at a single time point is indeed a snapshot view of a tremendously dynamic process 
and may not be representative of the full diversity of the disease.  The resulting inter-
tumoral heterogeneity of PDX models is a double edged sword.  It recapitulates the clinical 
environment, but also adds confounding factors.  One such confounding factor is the 
potential role of mutations, such as TP53 and KRAS, in PLK1 inhibitor sensitivity. 
Many studies have shown that generation of a PDX model in a murine host leads 
to clonal selection which may eventually result in a xenograft that differs from the original 
patient’s tumor (26, 114, 115). In the case of our study, the EMT status of mice was 
determined at an earlier passage before the experiment was carried out and clonal 
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evolution might have played a role in determining tumor response. The sample size for 
assessing EMT in each individual PDX model (n=4) is too low to make a correlation 
between EMT and response to PLK1 inhibitors. Another limitation of the PDX studies 
was that we only completed 4 PDX models and out statistical design dictated that at least 
13 models were needed to test our hypothesis.  Given the degree of intra-tumoral EMT 
heterogeneity, more PDX models may indeed be needed than calculated in the original 
study design.  
Although my data support my hypothesis that PLK1 inhibition leads to apoptosis 
in mesenchymal NSCLC but not in epithelial NSCLC, there are several limitations in the 
current data that need to be addressed in future studies, A few more PDX models must be 
used to check for PLK1 inhibition induced apoptosis in order to make a correlation 
between EMT status and response to PLK1 inhibitors. PDX models are highly 
heterogeneous and the response to PLK1 inhibitors might be difficult to correlate. The 
experiments might need to be carried out in early passage PDX models in order to reduce 
the clonal evolution of PDXs. The EMT status of the PDXs is defined by only two markers 
in the study, E-Cadherin and vimentin. A panel of markers will be used to determine the 
EMT phenotype of the PDX models. RNASeq analysis can be carried out in the PDX 
tumors to calculate the EMT score as well as identify novel biomarkers of response to 
PLK1 inhibition induced apoptosis in NSCLC.  
The 393P Vector cells, though inherently epithelial showed a decrease in tumor 
mass after PLK1 inhibition but it was not significant. The 393P ZEB1 cells, which are 
mesenchymal showed tumor regression after PLK1 inhibition. EMT related transcription 
factor ZEB1 and miR-200 are repressors and activators of E-cadherin expression 
respectively. The previous studies of our lab showed that manipulation of ZEB1 or 
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miR200 in vitro only slightly reversed sensitivity or resistance while a more robust 
response was seen with EMT induced by  TGFβ (67) (103).  Another finding from our 
previous study shows that epithelial NSCLC cells show cell arrest while the mesenchymal 
NSCLC cells undergo apoptosis after PLK1 inhibition (67) which needs to be confirmed 
in the PDX models.  
GEMMs that are created by introducing oncogenes or altering tumor suppressor 
genes in the mouse genome are widely used to study cancer biology (116). The KRAS and 
the KRAS/p53 conditional knock-in mouse models are two GEMMs that recapitulate 
characteristics of the human lung adenocarcinoma disease (117). The murine cell lines 
that were used in the study harbored KRAS and p53 mutations and had diverse EMT 
phenotypes. One limitation in our study was that we used a mouse model with two 
mutations that may increase sensitivity to PLK1 inhibition.   The previous study in our lab 
showed that there was no correlation between TP53 mutation status and PLK1 inhibitor 
sensitivity using 63 NSCLC cell lines.  Although KRAS mutation did predict sensitivity 
for 2 of the 3 PLK1 inhibitors tested, the correlation was not robust (67).  
Evaluation of lung cancer progression is often based on tumor measurements at 
the end of treatment. Histopathological analysis of lung tissue is the gold standard for 
assessment of lung tumorigenesis. Although these ex vivo procedures offer many 
opportunities to perform molecular and cellular analyses, they are limited to only one 
measurement and do not provide details about the dynamic processes that occur over time 
in vivo. Micro-computed tomography (micro-CT) has been incorporated to study the 
dynamic changes of tumor progression in preclinical models in a non-invasive manner 
(118). Although CT is technically challenging due to respiratory movement artifacts, it 
provides visual and quantitative information about the whole lung in a three-dimensional 
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manner with high resolution and sensitivity. More importantly, CT allows for longitudinal 
assessment of therapeutic interventions between different groups and the extent of disease 
in each individual mouse. CT is safe and there is no radiotoxicity to the lungs in mice with 
weekly CT imaging up to a period of 12 weeks despite receiving a relatively large radiation 
dose per micro-CT acquisition (119). For quantification of metastatic tumor burden, the 
methods that have been previously used relied on a Response Evaluation Criteria in Solid 
Tumors (RECIST)-like criteria wherein the maximal tumor diameter and the largest 
perpendicular diameter were measured in the coronal plane to calculate the tumor burden 
from the sum of cross products (98), tumor nodule segmentation (120), segmentation of 
aerated lung volume for tumor load quantification with respiratory gating (102), manual 
segmentation of chest space (121), individual nodule tracking (122), modeling tumors as 
ellipsoids (107) and volumetric measurement of combined tumor and vasculature from a 
threshold-based region growing algorithm with manual and semi-automated segmentation 
(99). The main drawbacks of these methods are that they are labor intensive, require 
specific skill sets in radiology and do not take all the thoracic metastases into 
consideration. We developed a micro-CT image analysis method to quantitatively measure 
tumor mass as a measure of metastatic tumor burden in lung cancer. This method of tumor 
mass calculation takes into account the metastatic tumors present in the thoracic cavity 
from the base of the lung to the top of the trachea. As the CT imaging is not respiratory 
gated, the probability of air escaping into the lungs and variance in the breathing period is 
high despite breath hold at the time of imaging. Also, tumor tissue and vasculature cannot 
be distinguished in the non-contrast micro-CT imaging as they have similar X-Ray 
densities. Thereby, one could expect that the tumor burden is proportional to the changes 
in the MTC in the adult mice. 
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Though β-Catenin was highly expressed in the resistant/epithelial NSCLC cell 
lines in comparison to the mesenchymal NSCLC cell lines, knockdown of β-Catenin was 
not sufficient to sensitize epithelial cells to PLK1 inhibition. This might be due to the fact 
that KD of β-Catenin alone does not change the epithelial phenotype. It is possible that β-
Catenin may be downstream to the key protein or pathway that mediates resistance to 
PLK1 inhibitors. Also, though SMAD4 is a member of the TGFβ pathway and studies 
have shown that increased expression of SMAD4 induces EMT or enhances the induction 
of EMT, KD of did not mediate resistance to PLK1 inhibitors in the mesenchymal NSCLC 
cell lines. This implies that there may be other factors in the TGFβ pathway that govern 
the mesenchymal phenotype of NSCLC cells. We identified PDK1 to decrease after PLK1 
inhibition in mesenchymal NSCLC but not epithelial NSCLC cell lines. PDK1 is a 
serine/threonine kinase which acts as a master kinase, phosphorylating and activating a 
subgroup of the cAMP-dependent, cGMP-dependent and protein kinase C (AGC) family 
of protein kinases such as AKT, p70RSK, p90RSK, SGK1, PAK1 to name a few. PDK1 
plays a central role in the transduction of signals from insulin by providing the activating 
phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets 
controlling cell proliferation and survival, as well as glucose and amino acid uptake and 
storage. A stable PDK1 overexpressing mesenchymal NSCLC cell line was established. 
It was observed that PDK1 overexpression slightly reduced sensitivity to the PLK1 
inhibitor Volasertib as observed by reduction in the expression of cleaved PARP and 
γH2AX. The limitation of this study is that only one NSCLC cell lines was used to study 
to the role of PDK1 overexpression in PLK1 inhibition-induced apoptosis. The response 
observed was minimal and it is possible that PDK1 may not be critical component in 
mediating resistance to PLK1 inhibitors. This might be due to the possibility that PDK1 
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is regulated by SRC which is downstream to the CMET-FAK-SRC signaling pathway 
which has been identified by our lab to mediate PLK1-inhibition induced apoptosis in 
NSCLC (103).  
A study in our lab showed that epithelial NSCLC cell lines are more resistant to 
PLK1 inhibition in comparison to mesenchymal NSCLC cell lines due to the differential 
regulation of CMET (103). The study shows that this is because of ligand independent 
activation of CMET in mesenchymal NSCLC cells in Integrin β1 due to increase in 
vimentin expression. Thus CMET activation can be used as a biomarker of response to 
PLK1 inhibition induced apoptosis (103).  
 In order to measure PLK1 inhibition induced apoptosis, TUNEL assay is being 
carried out to measure apoptotic cells in the vehicle and Volasertib treated PDX tumors 
and the epithelial and mesenchymal lung tumors. Pathological response will be used to 
correlate with PLK1 inhibitor sensitivity in the in vivo studies. Some of the additional 
studies that can be carried out includes inducing a mesenchymal-to-epithelial transition 
(MET) in mice by using mesenchymal cells with inducible miR200 expression. Other 
modalities by which EMT can be manipulated in vivo may be used to study PLK1 
inhibition induced apoptosis in NSCLC.  
 In conclusion, preliminary data suggests that mesenchymal NSCLC tumors are 
more sensitive to PLK1 inhibition in comparison to epithelial NSCLC tumors as seen in 
the PDX studies, the 344SQ mouse model and the 393P with ZEB1 overexpression mouse 
models. Though β-Catenin and SMAD4 KD did not reverse resistance or sensitivity to 
PLK1 inhibitors, it is a possibility that these are downstream to some key elements that 
drive resistance or sensitivity to PLK1 inhibitors. 
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